Genetic testing for prostate cancer has noticeably increased since the publication of landmark data showing testing may be underutilized when screening for and treating the second most common cancer in men.
Invitae’s panel is the most comprehensive and affordable genetic test available to urologists and oncologists who treat men with prostate cancer, establishing the company as a new leader in prostate cancer testing.
According to a study in the New England Journal of Medicine (NEJM), the incidence of germline mutations in men with metastatic prostate cancer is over 11% – higher than the historical rate for BRCA1 and BRCA2 mutations in high-risk breast cancer patients. Additionally, the study suggests that family history alone may be insufficient for gauging risk of prostate cancer and making treatment decisions. The study showed mutations in multiple DNA repair genes, including BRCA1, BRCA2, ATM, CHEK2, RAD51D, and PALB2, are significantly increased in metastatic prostate cancer patients. Related findings further support offering all men with metastatic prostate cancer germline genetic testing.
“I believe the NEJM study showing inherited DNA-repair gene defects are more common in prostate cancer patients than expected is among the most important data published this year,” said Oliver Sartor, MD, Laborde Professor of Cancer Research, Tulane Cancer Center in New Orleans.
The Invitae Prostate Cancer Panel analyzes up to 14 genes that are associated with a hereditary predisposition to prostate cancer. This panel may be considered for individuals with prostate cancer, especially early onset, aggressive or metastatic tumors. Other candidates for testing include patients whose history is suggestive of a hereditary cancer syndrome, such as a personal and/or family history of: